Delivery of the Cas9/sgRNA Ribonucleoprotein Complex in Immortalized and Primary Cells via Virus-like Particles ("Nanoblades")
March 31st, 2021
6.6K views
We have developed a simple and inexpensive protocol to load Cas9/single-guide RNA (sgRNA) ribonucleoprotein complexes within virus-like particles. These particles, called "Nanoblades", allow efficient delivery of the Cas9/sgRNA complex in immortalized and primary cells as well as in vivo.
Overview
This article presents a detailed protocol for the preparation and application of "Nanoblades"—virus-like particles (VLPs) engineered to deliver the Cas9 protein and single-guide RNA (sgRNA) complex for genome editing. Nanoblades offer a transient, efficient, and dose-dependent method for CRISPR-Cas9 delivery in both immortalized and primary cells, overcoming several limitations of classical viral vectors.
Key Study Components
Area of Science
- Genome editing
- Molecular biology
- Cell biology
- Gene delivery technologies
Background
- CRISPR-Cas9 has revolutionized genome editing in eukaryotic cells.
- Traditional viral vectors (e.g., lentiviruses, AAVs) efficiently deliver Cas9 and sgRNA but have drawbacks such as genomic integration, limited cargo capacity, and prolonged expression.
- Transient delivery of Cas9/sgRNA complexes can reduce off-target effects and avoid permanent genetic modifications.
- Nanoblades are VLPs based on murine leukemia virus (MLV) that deliver Cas9/sgRNA without encoding transgenes.
Purpose of Study
- To develop and demonstrate a simple, efficient, and cost-effective protocol for producing Nanoblades.
- To enable rapid and transient delivery of Cas9/sgRNA complexes to a variety of cell types.
- To provide a method that minimizes off-target effects and avoids integration of foreign DNA.
Methods Used
- Production of Nanoblades by transfecting HEK 293T cells with plasmids encoding Gag-Cas9 fusion proteins and sgRNA.
- Harvesting and purification of VLPs from culture supernatant using ultracentrifugation and sucrose cushion.
- Quantification of Cas9 content in Nanoblades via dot blot and chemiluminescence analysis.
- Transduction of target cells with purified Nanoblades and assessment of genome editing efficiency using T7 endonuclease assay and PCR.
Main Results
- Nanoblades enable rapid, efficient, and dose-dependent delivery of Cas9/sgRNA complexes to both immortalized and primary cells.
- The protocol is straightforward and cost-effective, suitable for most cell biology laboratories.
- Batch-to-batch variability in Cas9 loading and editing efficiency was observed, highlighting the importance of quality control.
- Nanoblades facilitated targeted genome editing, including site-directed insertion and inactivation of specific genes and noncoding RNAs.
Conclusions
- Nanoblades provide a versatile and transient CRISPR-Cas9 delivery platform that avoids the drawbacks of classical viral vectors.
- The method is accessible, scalable, and adaptable for various genome editing applications in vitro and in vivo.
- Proper cell seeding, pellet resuspension, and quality control are critical for optimal Nanoblade production and performance.
Frequently Asked Questions
What are Nanoblades and how do they differ from traditional viral vectors?
Nanoblades are virus-like particles engineered to deliver Cas9/sgRNA complexes without encoding transgenes, providing transient and efficient genome editing while avoiding genomic integration and prolonged expression associated with traditional viral vectors.
What are the main advantages of using Nanoblades for CRISPR-Cas9 delivery?
Nanoblades offer rapid, dose-dependent, and transient delivery of Cas9/sgRNA, reducing off-target effects and eliminating the risk of permanent genetic modification or transgene integration.
How are Nanoblades produced and purified?
Nanoblades are produced by transfecting HEK 293T cells with plasmids encoding Gag-Cas9 and sgRNA, followed by harvesting the culture supernatant, ultracentrifugation through a sucrose cushion, and resuspension of the VLP pellet.
How is the Cas9 content in Nanoblades quantified?
Cas9 content is measured using a dot blot assay on nitrocellulose membranes, with chemiluminescence detection and comparison to a standard curve generated from recombinant Cas9 dilutions.
What factors influence the efficiency of Nanoblade-mediated genome editing?
Efficiency depends on the quality and confluence of producer cells, proper resuspension of VLP pellets, and batch-to-batch variability in Cas9 loading, emphasizing the need for careful quality control.
Can Nanoblades be used for in vivo genome editing?
Yes, Nanoblades have been shown to enable in vivo genome editing, including applications in the liver of adult mice and in oocytes for generating transgenic animals.
What applications have Nanoblades enabled in research?
Nanoblades have facilitated studies of DNA repair mechanisms, targeted gene inactivation, and functional analysis of long noncoding RNAs in primary cells.
Executive Industry Relevance
Efficient, transient delivery of genome-editing complexes is a critical bottleneck in early-stage therapeutic discovery and functional genomics. Nanoblades—virus-like particles delivering Cas9/sgRNA ribonucleoproteins—address integration risk and off-target effects, supporting rapid hypothesis testing and mechanistic de-risking. This platform enables scalable, reproducible genome editing in both immortalized and primary cells, directly impacting target validation and preclinical model development.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables rapid interrogation of gene function through transient, non-integrative genome editing.
- Supports mechanistic de-risking by minimizing persistent Cas9 expression and off-target activity.
- Facilitates functional target validation in primary and disease-relevant cell systems.
- Improves predictive confidence for downstream portfolio triage.
Screening & Assay Development
- Prepares validated cell systems for high-content screening and phenotypic assays.
- Delivers quantitative, dose-dependent editing outputs for assay standardization.
- Enables reproducible, scalable workflows for compound evaluation and genetic perturbation.
- Reduces confounding effects from transgene integration or prolonged nuclease activity.
Translational & Preclinical Research
- Aligns genome editing with disease-relevant models for translational biomarker studies.
- Supports continuity from discovery through preclinical validation by enabling in vivo editing.
- Facilitates risk-adjusted advancement decisions based on transient, controlled gene modification.
- Enables functional studies of noncoding RNAs and DNA repair pathways in primary cells.
Pipeline & Workflow Integration
Nanoblades fit at the interface of early discovery and preclinical research, bridging target validation, assay development, and translational model generation.
- Discovery Biology: Provides rapid, integration-free genome editing for hypothesis testing and pathway analysis.
- Screening: Delivers standardized, quantitative editing for assay readiness and reproducibility.
- Analytics: Enables batch-specific quantification of Cas9 content and editing efficiency for robust data comparison.
- Translational Research: Supports in vivo genome editing and functional genomics in primary and disease-relevant systems.
- Enterprise Reuse: Offers a broadly adaptable, low-cost platform for repeated use across diverse R&D programs.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in gene function studies.
- Operational Value: Simplifies preparation, standardizes delivery, and enhances reproducibility across experiments.
- Strategic Value: Improves go/no-go decision quality and capital efficiency by minimizing late-stage biological risk.
- Portfolio Impact: Enables risk-adjusted prioritization and advancement of validated targets and models.
Implementation Considerations
- Requires expertise in cell culture, VLP production, and genome editing analytics.
- Needs access to ultracentrifugation and chemiluminescence quantification infrastructure.
- Demands rigorous batch-to-batch quality control for Cas9 loading and editing efficiency.
- Standardization of cell seeding and VLP resuspension is critical for reproducibility.
- Editing efficiency and reproducibility may vary with cell type and batch quality.
Biopharma FAQs
Why does null hypothesis testing matter for T7 endonuclease assay results?
Null hypothesis testing in T7 endonuclease assays ensures that observed genome editing is statistically significant and not due to random variation, supporting robust target validation decisions. This quantitative approach underpins confidence in functional genomics outputs for portfolio advancement.
How does independent variable isolation in Cas9 quantification support discovery?
Isolating Cas9 content via dot blot and chemiluminescence allows teams to attribute editing outcomes directly to RNP dose, reducing confounding variables. This clarity strengthens mechanistic insights and informs optimization in early discovery workflows.
What do quantitative dependent variable measurements in editing efficiency enable?
Quantitative measurements of editing efficiency, such as those from T7 endonuclease assays, enable direct comparison of batch performance and protocol optimization. These outputs support data-driven decisions in assay development and target prioritization.
Why are replication requirements critical for cross-functional Nanoblade use?
Replication ensures that Nanoblade-mediated editing is consistent across cell types and experimental runs, facilitating reliable data sharing between discovery, screening, and translational teams. This reproducibility is essential for cross-functional collaboration and enterprise-wide adoption.
What statistical analysis capabilities are needed before Nanoblade implementation?
Robust statistical analysis, including calibration curves and batch-to-batch comparison of Cas9 loading and editing efficiency, is required to validate Nanoblade performance. These capabilities ensure that only high-confidence, reproducible genome editing is advanced in the R&D pipeline.
